Phenylacetamides being FLT3 Inhibitors

A compound of formula

• wherein
• (i) each of R1 and R2, independently of the other, is selected from the group consisting of hydrogen, halo and C1-C7-alkyl;
• R3 is absent if Z is nitrogen or, if Z is C (carbon), is hydrogen, unsubstituted or substituted aryl or unsubstituted or substituted heterocyclyl;
• X is N (nitrogen) or CH (hydrogen-substituted carbon),
• Y is CH or N,
• Z is C or N, and
• Q is a group of the formula
• wherein
• (a) R4 is hydrogen, halo, unsubstituted or substituted amino, unsubstituted or substituted aryl, unsubstituted or substituted heterocyclyl bound via a ring atom other than nitrogen, unsubstituted or substituted cycloalkyl, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl or unsubstituted or substituted alkynyl;
• R5 is 1-methyl-piperidin-4-yloxy), 1-methyl-piperidin-4-yl, 2-dimethylamino-ethyl or 4-ethyl-piperazin-1-yl;
• and
• R6 is hydrogen, unsubstituted or substituted cycloalkyl or unsubstituted or substituted alkyl;
• or
• (b) R4 is 1-methyl-piperidin-4-ylmethyl), 1-ethyl-piperidin-4-ylmethyl, 1-methyl-piperidin-4-yloxy or 1-isopropyl-piperidin-4-ylmethyl;
• R5 is hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted amino, unsubstituted or substituted aryl or unsubstituted or substituted heterocyclyl;
• and
• R6 is hydrogen, unsubstituted or substituted cycloalkyl or unsubstituted or substituted alkyl;
• where the asterisk * in formula (A) marks the bond through which the moiety is bound to the NH of the amide group in formula I;
• and
• either each of R9 and R10, independently of the other, is selected from the group consisting of hydrogen, hydroxyl and C1-C7-alkyl;
• or
• R9 and R10 together represent oxo;
• or
• R1 and R9 together form a group —C(O)—CH2— or —CH2—CH2—, R2 is selected from the group consisting of hydrogen, halo and C1-C7-alkyl, and R10 represents hydrogen;
• or
• (ii) which is selected from the group consisting of
• 2-(4-Benzoimidazol-1-yl-phenyl)-N-[4-(4-isopropyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-acetamide,
• 2-(4-Benzoimidazol-1-yl-phenyl)-N-(4-diethylaminomethyl-3-trifluoromethyl-phenyl)-acetamide),
• 2-(4-Benzoimidazol-1-yl-phenyl)-N-(4-pyrrolidin-1-ylmethyl-3-trifluoromethyl-phenyl)-acetamide,
• 2-(2-Chloro-4-imidazo[4,5-b]pyridin-3-yl-phenyl)-N-(4-diethylaminomethyl-3-trifluoromethyl-phenyl)-acetamide,
• 2-(2-Chloro-4-imidazo[4,5-b]pyridin-3-yl-phenyl)-N-(4-pyrrolidin-1-ylmethyl-3-trifluoromethyl-phenyl)-acetamide,
• N-[3-(4-Ethyl-piperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-2-(4-imidazo[4,5-b]pyridin-3-yl-phenyl)-acetamide,
• N-(3-Diethylaminomethyl-5-trifluoromethyl-phenyl)-2-(4-imidazo[4,5-b]pyridin-3-yl-phenyl)-acetamide,
• 2-(4-Benzoimidazol-1-yl-phenyl)-N-(3-diethylaminomethyl-5-trifluoromethyl-phenyl)-acetamide,
• 2-(4-Imidazo[4,5-b]pyridin-3-yl-phenyl)-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-acetamide,
• 2-(4-Imidazo[4,5-b]pyridin-3-yl-2-methyl-phenyl)-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-acetamide,
• 2-(4-Imidazo[4,5-b]pyridin-3-yl-2-methyl-phenyl)-N-[3-(4-methyl-piperazin-1-yl)-5-trifluoromethyl-phenyl]-acetamide,
• N-[3-(4-Ethyl-piperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-2-(4-imidazo[4,5-b]pyridin-3-yl-2-methyl-phenyl)-acetamide,
• 2-(2-Chloro-4-imidazo[4,5-b]pyridin-3-yl-phenyl)-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-acetamide,
• 2-(4-Benzoimidazol-1-yl-phenyl)-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-acetamide,
• 2-(4-Benzoimidazol-1-yl-phenyl)-N-[3-(4-ethyl-piperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-acetamide, and
• 2-(4-Imidazo[4,5-b]pyridin-3-yl-2-methyl-phenyl)-N-[4-(1-methyl-piperidin-4-ylmethyl)-3-trifluoromethyl-phenyl]-acetamide.